Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide--pharmacologic overview.

G Sarosy1

  • 1Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.

Seminars in Oncology
|February 1, 1989
PubMed
Summary
This summary is machine-generated.

Ifosfamide, a nitrogen mustard, offers distinct clinical activity and toxicity compared to cyclophosphamide due to structural differences. Uroprotection with mesna enables higher doses, improving ifosfamide

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survival.

Annals of oncology : official journal of the European Society for Medical Oncology·1999
Same author

Future directions with taxane therapy.

Hematology/oncology clinics of North America·1999
Same author

Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.

Biopharmaceutics & drug disposition·1997
Same author

Borderline ovarian tumors.

The American journal of medicine·1996
Same author

A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.

Gynecologic oncology·1996
Same author

Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.

Cancer research·1996
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Ifosfamide and cyclophosphamide are oxazaphosphorine nitrogen mustards with over 20 years of history.
  • A key structural difference lies in the attachment of chloroethyl groups, influencing their pharmacologic behavior.

Purpose of the Study:

  • To compare the clinical activity and toxicity profiles of ifosfamide and cyclophosphamide.
  • To investigate the impact of structural variations on drug efficacy and side effects.
  • To explore the role of uroprotection in mitigating ifosfamide toxicity.

Main Methods:

  • Review of initial clinical trials for ifosfamide.
  • Analysis of dose-dependent toxicity, specifically hemorrhagic cystitis.
  • Evaluation of the efficacy of systemic thiol uroprotectors like mesna.

Related Experiment Videos

Main Results:

  • Hemorrhagic cystitis was a dose-limiting toxicity in early ifosfamide trials.
  • Mesna effectively mitigates ifosfamide-induced urotoxicity, allowing for higher dosages.
  • Current ifosfamide administration involves daily dosing for five days with mesna.

Conclusions:

  • Structural differences between ifosfamide and cyclophosphamide explain variations in clinical use.
  • Mesna has revolutionized ifosfamide therapy by managing its primary toxicity.
  • Understanding ifosfamide's pharmacology and metabolism is crucial for optimizing treatment schedules.